Ischaemic mitral regurgitation: pathophysiology, outcomes and the conundrum of treatment

Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents the valvular consequences of increased tethering forces (papillary muscles displacement leading t...

Full description

Saved in:
Bibliographic Details
Published inEuropean heart journal Vol. 31; no. 24; pp. 2996 - 3005
Main Authors Piérard, Luc A., Carabello, Blase A.
Format Journal Article Web Resource
LanguageEnglish
Published Oxford Oxford University Press 01.12.2010
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Ischaemic mitral regurgitation is a frequent complication of left ventricular global or regional pathological remodelling due to chronic coronary artery disease. It is not a valve disease but represents the valvular consequences of increased tethering forces (papillary muscles displacement leading to a more apical position of the leaflets and their coaptation point) and reduced closing forces (reduced contractility, dyssynchrony of the papillary muscles, intra-left ventricular dyssynchrony). Although mitral regurgitation has an unloading effect and reduces impedance, the volume overload begets further left ventricular dilatation, increases ventricular wall stress leading to worsened performance. Ischaemic mitral regurgitation is characteristically dynamic: its severity may vary with haemodynamic conditions. Both the severity of ischaemic mitral regurgitation and its dynamic component worsen prognosis. There are numerous possible treatment modalities, but the management of the individual patient remains difficult. Medical therapy is mandatory; revascularization procedures are frequently not sufficient to reduce mitral regurgitation; the role of combined surgical therapy by mitral valve repair is not yet defined in the absence of large randomized trial. Some patients are good candidates for cardiac resynchronization therapy that may reduce the amount of regurgitation. New therapeutic targets are under investigation.
Bibliography:ArticleID:ehq411
ark:/67375/HXZ-3LTGHHKW-2
istex:FC49B54EF114245A5B8D5E019C55AC6FAE87982F
href:ehq411.pdf
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
scopus-id:2-s2.0-78650343175
ISSN:0195-668X
1522-9645
1522-9645
DOI:10.1093/eurheartj/ehq411